-28.1% · 90d
$4.27
-0.14 (-3.07%)
News
(1)April 2026
CTMX proposes increasing authorized shares to 600 million for growth
CTMXCytomX Therapeutics, Inc.
# 📰 What This Document Is 📑 This is a Preliminary Proxy Statement (PRE 14A), which is a crucial document filed with the SEC. Think of it as the official rulebook for the company’s annual shareholder meeting. It's not a financial report, but rather a detailed guide explaining exactly what sharehol
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%